What Happened? Shares of life sciences company Thermo Fisher (NYSE:TMO) fell 10.5% in the afternoon session after the company reported first-quarter results ...
Life sciences company Thermo Fisher (NYSE:TMO) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 6.2% year on year to $11.01 billion. Its n...
Life sciences company Thermo Fisher (NYSE:TMO) will be reporting earnings this Thursday before the bell. Here’s what to look for. Thermo Fisher beat analysts...
The Iran conflict has given investors a reason to sell just about everything. The Dow is in correction territory. Oil prices have surged. Entire sectors are trading as if a recession is already here. But inside those beaten-down groups, a handful of stocks are quietly doing something different.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a pioneer in AI-driven clinical research, for a staggering $47.8 billion. The deal represents the largest "Tech-Bio" merger in
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
INDIANAPOLIS — In a move that has sent shockwaves through the global financial markets, Eli Lilly and Company (NYSE: LLY) announced early this morning, April 1, 2026, a definitive agreement to acquire Contessa, a powerhouse in clinical research and next-generation pharmaceutical development. The massive $47.8 billion all-cash transaction represents the
As the first quarter of 2026 draws to a close, the healthcare and life sciences sectors are grappling with a "new normal" defined by capital conservatism and geopolitical friction. Industry bellwethers, once buoyed by post-pandemic expansion and aggressive R&D spending, are now issuing sober forecast revisions that reflect a
WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the life sciences sector. Reporting its fourth-quarter 2025 results on January 29, 2026, the company delivered a robust earnings
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
As of February 17, 2026, Danaher Corporation (NYSE: DHR) finds itself at a pivotal juncture in its multi-decade evolution. Once the darling of the "compounding" investment community, the Washington, D.C.-based life sciences giant has recently seen its share price retreat from 2025 highs, currently trading down approximately 11% year-to-date. This volatility follows a complex narrative: [...]
